{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T03:02:56Z","timestamp":1784516576592,"version":"3.55.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,19]]},"DOI":"10.7759\/cureus.112972","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T02:50:54Z","timestamp":1784515854000},"source":"Crossref","is-referenced-by-count":0,"title":["Cardiac Troponin Elevation Beyond Type 1 Myocardial Infarction: A Systematic Review of Prognostic Significance and Cardiovascular Risk Stratification"],"prefix":"10.7759","author":[{"given":"Mohammad","family":"Abuzenah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabia","family":"Zameer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahil","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaid","family":"Al Ghananeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palak","family":"Batra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaleem","family":"Khaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31923-8","article-title":"High-sensitivity troponin in the evaluation of patients with suspected acute coronary syndrome: a stepped-wedge, cluster-randomised controlled trial","volume":"392","author":"Shah AS","year":"2018","unstructured":"Shah AS, Anand A, Strachan FE, et al.. High-sensitivity troponin in the evaluation of patients with suspected acute coronary syndrome: a stepped-wedge, cluster-randomised controlled trial. Lancet. 2018, 392:919-28. 10.1016\/S0140-6736(18)31923-8","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae803","article-title":"Type 2 myocardial infarction: challenges in diagnosis and treatment","volume":"46","author":"Chapman AR","year":"2025","unstructured":"Chapman AR, Taggart C, Boeddinghaus J, Mills NL, Fox KA. Type 2 myocardial infarction: challenges in diagnosis and treatment. Eur Heart J. 2025, 46:504-17. 10.1093\/eurheartj\/ehae803","journal-title":"Eur Heart J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jscai.2022.100395","article-title":"Clinical characteristics, outcomes, and epidemiological trends of patients admitted with type 2 myocardial infarction","volume":"1","author":"Rogers E","year":"2022","unstructured":"Rogers E, Torres C, Rao SV, Donatelle M, Beohar N. Clinical characteristics, outcomes, and epidemiological trends of patients admitted with type 2 myocardial infarction. J Soc Cardiovasc Angiogr Interv. 2022, 1:100395. 10.1016\/j.jscai.2022.100395","journal-title":"J Soc Cardiovasc Angiogr Interv"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy462","article-title":"Fourth universal definition of myocardial infarction (2018)","volume":"40","author":"Thygesen K","year":"2019","unstructured":"Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019, 40:237-69. 10.1093\/eurheartj\/ehy462","journal-title":"Eur Heart J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.040631","article-title":"Assessment and treatment of patients with type 2 myocardial infarction and acute nonischemic myocardial injury","volume":"140","author":"DeFilippis AP","year":"2019","unstructured":"DeFilippis AP, Chapman AR, Mills NL, de Lemos JA, Arbab-Zadeh A, Newby LK, Morrow DA. Assessment and treatment of patients with type 2 myocardial infarction and acute nonischemic myocardial injury. Circulation. 2019, 140:1661-78. 10.1161\/CIRCULATIONAHA.119.040631","journal-title":"Circulation"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.042960","article-title":"High-sensitivity cardiac troponin and the universal definition of myocardial infarction","volume":"141","author":"Chapman AR","year":"2020","unstructured":"Chapman AR, Adamson PD, Shah AS, et al.. High-sensitivity cardiac troponin and the universal definition of myocardial infarction. Circulation. 2020, 141:161-71. 10.1161\/CIRCULATIONAHA.119.042960","journal-title":"Circulation"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.059678","article-title":"High-sensitivity cardiac troponin and the 2021 AHA\/ACC\/ASE\/CHEST\/SAEM\/SCCT\/SCMR guidelines for the evaluation and diagnosis of acute chest pain","volume":"146","author":"Sandoval Y","year":"2022","unstructured":"Sandoval Y, Apple FS, Mahler SA, Body R, Collinson PO, Jaffe AS. High-sensitivity cardiac troponin and the 2021 AHA\/ACC\/ASE\/CHEST\/SAEM\/SCCT\/SCMR guidelines for the evaluation and diagnosis of acute chest pain. Circulation. 2022, 146:569-81. 10.1161\/CIRCULATIONAHA.122.059678","journal-title":"Circulation"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/1751143719870095","article-title":"High sensitivity troponin measurement in critical care: flattering to deceive or 'never means nothing'?","volume":"21","author":"Hinton J","year":"2020","unstructured":"Hinton J, Mariathas M, Grocott MP, Curzen N. High sensitivity troponin measurement in critical care: flattering to deceive or 'never means nothing'?. J Intensive Care Soc. 2020, 21:232-40. 10.1177\/1751143719870095","journal-title":"J Intensive Care Soc"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden JA","year":"2013","unstructured":"Hayden JA, van der Windt DA, Cartwright JL, C\u00f4t\u00e9 P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med. 2013, 158:280-6. 10.7326\/0003-4819-158-4-201302190-00009","journal-title":"Ann Intern Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne JA","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al.. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016, 355:i4919. 10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7326\/M18-1376","article-title":"PROBAST: a tool to assess the risk of bias and applicability of prediction model studies","volume":"170","author":"Wolff RF","year":"2019","unstructured":"Wolff RF, Moons KG, Riley RD, et al.. PROBAST: a tool to assess the risk of bias and applicability of prediction model studies. Ann Intern Med. 2019, 170:51-8. 10.7326\/M18-1376","journal-title":"Ann Intern Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx457","article-title":"Discrimination of patients with type 2 myocardial infarction","volume":"38","author":"Neumann JT","year":"2017","unstructured":"Neumann JT, S\u00f6rensen NA, R\u00fcbsamen N, et al.. Discrimination of patients with type 2 myocardial infarction. Eur Heart J. 2017, 38:3514-20. 10.1093\/eurheartj\/ehx457","journal-title":"Eur Heart J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0233178","article-title":"Associations of antithrombotic agent use with clinical outcomes in critically ill patients with\u00a0troponin I elevation in the absence of acute coronary syndrome","volume":"15","author":"Tsai CT","year":"2020","unstructured":"Tsai CT, Lu YW, Chou RH, et al.. Associations of antithrombotic agent use with clinical outcomes in critically ill patients with\u00a0troponin I elevation in the absence of acute coronary syndrome. PLoS One. 2020, 15:e0233178. 10.1371\/journal.pone.0233178","journal-title":"PLoS One"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/ehjqcco\/qcx022","article-title":"High-sensitivity cardiac troponin I and risk of heart failure in patients with suspected acute coronary syndrome: a cohort study","volume":"4","author":"Stelzle D","year":"2018","unstructured":"Stelzle D, Shah AS, Anand A, et al.. High-sensitivity cardiac troponin I and risk of heart failure in patients with suspected acute coronary syndrome: a cohort study. Eur Heart J Qual Care Clin Outcomes. 2018, 4:36-42. 10.1093\/ehjqcco\/qcx022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1019","article-title":"Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial","volume":"20","author":"Greene SJ","year":"2018","unstructured":"Greene SJ, Butler J, Fonarow GC, et al.. Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial. Eur J Heart Fail. 2018, 20:281-91. 10.1002\/ejhf.1019","journal-title":"Eur J Heart Fail"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2256","article-title":"Concentration-dependent clinical and prognostic importance of high-sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR-Reduced trial","volume":"23","author":"Packer M","year":"2021","unstructured":"Packer M, Januzzi JL, Ferreira JP, et al.. Concentration-dependent clinical and prognostic importance of high-sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR-Reduced trial. Eur J Heart Fail. 2021, 23:1529-38. 10.1002\/ejhf.2256","journal-title":"Eur J Heart Fail"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz240","article-title":"Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial","volume":"40","author":"Morrow DA","year":"2019","unstructured":"Morrow DA, Velazquez EJ, DeVore AD, et al.. Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial. Eur Heart J. 2019, 40:3345-52. 10.1093\/eurheartj\/ehz240","journal-title":"Eur Heart J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/jcm15031279","article-title":"Type 2 myocardial infarction: navigating diagnostic pathways and therapeutic crossroads between invasive and conservative strategies","volume":"15","author":"Cinconze S","year":"2026","unstructured":"Cinconze S, Bernelli C, Giordana F. Type 2 myocardial infarction: navigating diagnostic pathways and therapeutic crossroads between invasive and conservative strategies. J Clin Med. 2026, 15:10.3390\/jcm15031279","journal-title":"J Clin Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.08.750","article-title":"2022 ACC expert consensus decision pathway on the evaluation and disposition of acute chest pain in the emergency department: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"80","author":"Kontos MC","year":"2022","unstructured":"Kontos MC, de Lemos JA, Deitelzweig SB, et al.. 2022 ACC expert consensus decision pathway on the evaluation and disposition of acute chest pain in the emergency department: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022, 80:1925-60. 10.1016\/j.jacc.2022.08.750","journal-title":"J Am Coll Cardiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/508976-cardiac-troponin-elevation-beyond-type-1-myocardial-infarction-a-systematic-review-of-prognostic-significance-and-cardiovascular-risk-stratification","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T02:50:55Z","timestamp":1784515855000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/508976-cardiac-troponin-elevation-beyond-type-1-myocardial-infarction-a-systematic-review-of-prognostic-significance-and-cardiovascular-risk-stratification"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,19]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.112972","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,19]]}}}